CV Lattes
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Jacqueline Cavalcante Silva in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Thiazolidinediones (TZDs) comprise a class of hypoglycemic drugs which reduce insulin resistance in peripheral tissues. Evidences indicate that TZDs hypoglycemic effects is peroxisome proliferator-activated receptors (PPARs) mediated, on its gamma, alpha and/or beta/delta isoforms. Initially, three TZDs were approved to clinical use: troglitazone, rosiglitazone and pioglitazone. Recently,…
This project aims to investigate the effects of new thiazolidinediones (TZDs) chemically modified in an animal model of metabolic syndrome and to compare the effects obtained with rosiglitazone, a TZD previously studied and established commercially. This assessment will cover the effects of thiazolidinediones on the expression of modified pro-inflammatory genes, anti-inflammatory liver an…
The thiazolidinediones (TZDs) class comprises drugs with hypoglycemic effects by activation of alpha/gamma peroxisome proliferator-activated receptor isoforms (PPAR±, PPAR³ and PPAR ²/´). Besides insulin sensitizer effect, some clinical studies have linked TZDs treatment to anti-inflammatory potential probably due to PPAR³ agonism. Although these beneficial effects, prolonged use of TZDs …
The thiazolidinediones (TZDs) class comprises drugs with hypoglycemic effects by activation of alpha/gamma peroxisome proliferator-activated receptor isoforms (PPAR±, PPAR³ and PPAR ²/´). Besides insulin sensitizer effect, some clinical studies have linked TZDs treatment to anti-inflammatory potential probably due to PPAR³ agonism. Although these beneficial effects, prolonged use of TZDs …
Preliminary results obtained in the Masters project "Investigation of new thiazolidine compounds effects in animal model of metabolic syndrome", demonstrated that this new thiazolidine compound, GQ-11, has in vivo immunomodulatory, anti-inflammatory and hypoglycemic effects, besides of angiogenic actions showed in previous in vitro studies of our group, what predicts a promising therapeut…
| 3 / 2 | Completed scholarships in Brazil |
| 3 / 3 | Completed scholarships abroad |
| 6 / 5 | All Scholarships |
| Associated processes | |